FDA ANTI-OBESITY DRUG REVIEWS SHOULD FOCUS ON "PATHOGENESIS OF OBESITY
Executive Summary
FDA ANTI-OBESITY DRUG REVIEWS SHOULD FOCUS ON "PATHOGENESIS OF OBESITY as a chronic disease, and [the agency should] evaluate drugs for its treatment in that light," the Institute of Medicine recommends in a report on obesity released Dec. 6. IoM suggests that anti-obesity drugs be "judged effective if they can produce small but medically significant weight losses and be used for maintenance of weight loss."